Q&A With Ayman Tourbah From University Hospital of Reims: Treatment For Progressive Multiple Sclerosis Still Lags Behind Relapsing Form

Video

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form. That is starting to change as more therapies and medications work their way through the regulatory approval process.

Professor Ayman Tourbah from the University Hospital of Reims in France discussed what can be done to help level the playing field in the treatment of this form of the disease during the ECTRIMS conference in Barcelona.

While there are considerably more treatment options available for relapsing multiple sclerosis there is considerable research being conducted to help patients with primary progressive multiple sclerosis.

Recent Videos
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
© 2024 MJH Life Sciences

All rights reserved.